LAZCLUZE™ (lazertinib)
- Search Medical Information
- Disease state information & resources
- Guidelines
- Pivotal clinical trial publications
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer